We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Calypso Biotech

News List

Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing contractpharma
June 19, 2020
AGC Biologics scales up production to support Calypso’s clinical trials.
Calypso Biotech BV Secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases b3cnewswire
March 01, 2019
Calypso Biotech, an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing co-led by Gilde Healthcare and Inkef Capital. They are joined by Johnson & Johnson Innovatio
Calypso Biotech Licenses CALY-001 Best-In-Class Anti-MMP-9 Antibody to EA Pharma b3cnewswire
April 01, 2017
Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001.